- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
Announcements
- Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
- Faridoxorubicin Program Clinical Updates
- Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
- FDA Clearance of IND Application for AVA6103
- Avacta Announces Year-end Trading Update
- Year-end trading update
- Appointment of Nominated Adviser & TVR
- Avacta reports new AVA6103 pharmacology data
- Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
- Faridoxorubicin Phase 1b SGC data
More ▼
Key statistics
On Friday, Avacta Group PLC (AVCT:LSE) closed at 60.50, -27.98% below its 52-week high of 84.00, set on Dec 17, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 60.00 |
|---|---|
| High | 60.90 |
| Low | 60.50 |
| Bid | 54.00 |
| Offer | 64.00 |
| Previous close | 60.00 |
| Average volume | 2.00m |
|---|---|
| Shares outstanding | 440.42m |
| Free float | 426.19m |
| P/E (TTM) | -- |
| Market cap | 264.25m GBP |
| EPS (TTM) | -0.0891 GBP |
Data delayed at least 20 minutes, as of Feb 06 2026 17:09 GMT.
More ▼
